Kathleen M. Mazzarella
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Waste Management (WM) Valuation and Earnings Outlook in Focus. Recent coverage focuses on Waste Management's valuation as the company heads into earnings, with debate over whether current prices align with future cash flows. Several analyses compare Waste Management to industry peers, examining dividend payouts and long-term value potential. The stock has also drawn attention for unusual trading volume and price gaps in recent sessions.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cigna Focuses on Data-Driven Care and Valuation Metrics. Recent coverage highlights Cigna's strategic shift toward data-driven care through its Health Sense initiative, positioning it as a key differentiator in the healthcare sector. Analysts are also examining the stock's valuation, noting a forward P/E that suggests value despite ongoing earnings risks. With the stock trading near its 52-week high, these developments provide context for its current market position relative to peers like UnitedHealth.
Transaction History
| CNM | ▲ Buy | Grant | 2,799 | $0 | 6/23/2026 | View on chart |
| WM | ▲ Buy | Grant | 1,314 | $290K | 5/15/2026 | View on chart |
| CI | ▲ Buy | Grant | 782 | $0 | 4/22/2026 | View on chart |
| WM | ▲ Buy | Grant | 1,063 | $242K | 7/15/2025 | View on chart |
| CNM | ▲ Buy | Grant | 2,189 | $0 | 6/24/2025 | View on chart |
| CI | ▲ Buy | Grant | 638 | $0 | 4/23/2025 | View on chart |
| WM | ▲ Buy | Grant | 674 | $140K | 1/15/2025 | View on chart |
| WM | ▲ Buy | Grant | 651 | $140K | 7/15/2024 | View on chart |
| CNM | ▲ Buy | Grant | 2,449 | $0 | 6/26/2024 | View on chart |
| CI | ▲ Buy | Grant | 539 | $0 | 4/24/2024 | View on chart |
| WM | ▲ Buy | Grant | 777 | $140K | 1/15/2024 | View on chart |
| WM | ▲ Buy | Grant | 834 | $140K | 7/15/2023 | View on chart |
| CNM | ▲ Buy | Grant | 3,927 | $0 | 6/28/2023 | View on chart |
| WM | ▲ Buy | Grant | 111 | $19K | 5/8/2023 | View on chart |
| CI | ▲ Buy | Grant | 765 | $0 | 4/26/2023 | View on chart |
| WM | ▲ Buy | Grant | 588 | $90K | 1/15/2023 | View on chart |
| WM | ▲ Buy | Grant | 593 | $90K | 7/15/2022 | View on chart |
| CI | ▲ Buy | Grant | 757 | $0 | 4/27/2022 | View on chart |
| CI | ▲ Buy | Grant | 199 | $0 | 2/28/2022 | View on chart |
| WM | ▲ Buy | Grant | 528 | $83K | 1/15/2022 | View on chart |
| CI | ▲ Buy | Grant | 247 | $0 | 11/30/2021 | View on chart |
| CI | ▲ Buy | Grant | 224 | $0 | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
CNM Compared to KMT; Mixed Views on Value
CNM is being compared to KMT in a recent Yahoo article that asks which stock offers better value. Another piece lists two strengths of CNM and one reason to remain cautious. The comparison highlights that while CNM has some attractive fundamentals, there are also concerns that could temper enthusiasm.
CNM Compared to KMT; Mixed Views on Value. CNM is being compared to KMT in a recent Yahoo article that asks which stock offers better value. Another piece lists two strengths of CNM and one reason to remain cautious. The comparison highlights that while CNM has some attractive fundamentals, there are also concerns that could temper enthusiasm.